NYSE:HAE

Haemonetics (HAE) Stock Price, News & Analysis

$83.61
+2.37 (+2.92%)
(As of 04/22/2024 ET)
Today's Range
$80.90
$83.85
50-Day Range
$71.25
$87.05
52-Week Range
$70.74
$95.26
Volume
402,130 shs
Average Volume
413,916 shs
Market Capitalization
$4.25 billion
P/E Ratio
33.99
Dividend Yield
N/A
Price Target
$104.67

Haemonetics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
25.2% Upside
$104.67 Price Target
Short Interest
Healthy
4.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.54
Upright™ Environmental Score
News Sentiment
0.74mentions of Haemonetics in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
7.34%
From $3.95 to $4.24 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.73 out of 5 stars

Medical Sector

70th out of 910 stocks

Surgical & Medical Instruments Industry

14th out of 97 stocks

HAE stock logo

About Haemonetics Stock (NYSE:HAE)

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

HAE Stock Price History

HAE Stock News Headlines

Haemonetics Co. (NYSE:HAE) Short Interest Down 6.4% in March
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Haemonetics Corporation
Haemonetics Corp.
See More Headlines
Receive HAE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
4/22/2024
Next Earnings (Confirmed)
5/09/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
CUSIP
40502410
Employees
3,034
Year Founded
1971

Price Target and Rating

Average Stock Price Target
$104.67
High Stock Price Target
$115.00
Low Stock Price Target
$94.00
Potential Upside/Downside
+25.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$115.40 million
Pretax Margin
12.68%

Debt

Sales & Book Value

Annual Sales
$1.17 billion
Cash Flow
$5.12 per share
Book Value
$16.22 per share

Miscellaneous

Free Float
49,877,000
Market Cap
$4.25 billion
Optionable
Optionable
Beta
0.36

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

HAE Stock Analysis - Frequently Asked Questions

Should I buy or sell Haemonetics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HAE shares.
View HAE analyst ratings
or view top-rated stocks.

What is Haemonetics' stock price target for 2024?

2 equities research analysts have issued 12-month price objectives for Haemonetics' shares. Their HAE share price targets range from $94.00 to $115.00. On average, they expect the company's stock price to reach $104.67 in the next twelve months. This suggests a possible upside of 25.2% from the stock's current price.
View analysts price targets for HAE
or view top-rated stocks among Wall Street analysts.

How have HAE shares performed in 2024?

Haemonetics' stock was trading at $85.51 on January 1st, 2024. Since then, HAE stock has decreased by 2.2% and is now trading at $83.61.
View the best growth stocks for 2024 here
.

Are investors shorting Haemonetics?

Haemonetics saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 2,040,000 shares, a decline of 6.4% from the March 15th total of 2,180,000 shares. Based on an average trading volume of 455,600 shares, the short-interest ratio is currently 4.5 days. Currently, 4.1% of the shares of the company are sold short.
View Haemonetics' Short Interest
.

When is Haemonetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our HAE earnings forecast
.

How can I listen to Haemonetics' earnings call?

Haemonetics will be holding an earnings conference call on Thursday, May 9th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) posted its quarterly earnings results on Thursday, February, 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.94 by $0.10. The medical instruments supplier had revenue of $336.20 million for the quarter, compared to the consensus estimate of $320.84 million. Haemonetics had a net margin of 9.97% and a trailing twelve-month return on equity of 22.37%. The firm's revenue for the quarter was up 10.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.85 earnings per share.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics issued an update on its FY24 earnings guidance on Thursday, February, 8th. The company provided earnings per share (EPS) guidance of $3.90-4.00 for the period, compared to the consensus estimate of $3.89. The company issued revenue guidance of ~$1.28-1.31 billion, compared to the consensus revenue estimate of $1.27 billion.

What is Christopher Simon's approval rating as Haemonetics' CEO?

48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by many different retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.99%), Los Angeles Capital Management LLC (0.05%), CWM LLC (0.05%), Dynamic Advisor Solutions LLC (0.04%), Cardinal Capital Management (0.03%) and State of Michigan Retirement System (0.02%). Insiders that own company stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Laurie A Miller, Mark W Kroll, Mark W Kroll, Michelle L Basil, Michelle L Basil, Stewart W Strong and William P Mr Burke.
View institutional ownership trends
.

How do I buy shares of Haemonetics?

Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:HAE) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners